Cargando…

A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)

Introduction: Over the past decade, the treatment of metastatic castration-sensitive prostate cancer (mCSPC) has changed significantly. Current guidelines suggest the use of androgen deprivation therapy (ADT) plus an additional systemic therapy, regardless of disease burden and risk, based on phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Karim, Safiya, Lowther, Jennifer, Gyulay, Gabriel, O’Sullivan, Dylan, Wallis, Christopher J. D., Yip, Steven M., Brenner, Darren R., Boyne, Devon J., Cheung, Winson Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528640/
https://www.ncbi.nlm.nih.gov/pubmed/37754506
http://dx.doi.org/10.3390/curroncol30090591
_version_ 1785111292765274112
author Karim, Safiya
Lowther, Jennifer
Gyulay, Gabriel
O’Sullivan, Dylan
Wallis, Christopher J. D.
Yip, Steven M.
Brenner, Darren R.
Boyne, Devon J.
Cheung, Winson Y.
author_facet Karim, Safiya
Lowther, Jennifer
Gyulay, Gabriel
O’Sullivan, Dylan
Wallis, Christopher J. D.
Yip, Steven M.
Brenner, Darren R.
Boyne, Devon J.
Cheung, Winson Y.
author_sort Karim, Safiya
collection PubMed
description Introduction: Over the past decade, the treatment of metastatic castration-sensitive prostate cancer (mCSPC) has changed significantly. Current guidelines suggest the use of androgen deprivation therapy (ADT) plus an additional systemic therapy, regardless of disease burden and risk, based on phase 1 evidence showing improved overall survival. We sought to describe treatment patterns of patients with mCSPC in the province of Alberta. Methods: This was a retrospective, population-based, cohort study of male patients aged ≥18 with mCSPC at the time of diagnosis and who initiated ADT between 1 January 2016 and 31 December 2020. Data were obtained from the Alberta Cancer Registry. Patients were assigned to an ADT-alone cohort or a treatment intensification cohort (cohorts 2–5). The primary objectives of this study were to describe baseline characteristics and the treatment of mCSPC patients who initiated ADT with or without treatment intensification. Overall survival between cohorts was a secondary objective. Descriptive statistics were used to describe differences in baseline characteristics of each cohort. Overall survival was calculated using the Kaplan–Meier method. All statistical tests were two-sided and are used to call out likely cohort differences descriptively. Results: Between 1 January 2016 and 31 December 2020, we identified a total of 960 patients with mCSPC (median age 74 years, IQR 66–82). Most patients received ADT alone (67%), followed by ADT plus abiraterone (18%), ADT plus docetaxel (12%), and ADT plus enzalutamide or apalutamide (3%). Over the study period, we observed an increase in the utilization of treatment intensification over time, in particular, the increased use of androgen-receptor-axis-targeted (ARAT) therapies. Patients who received ADT alone were older, were more likely to have more than one comorbid condition, had fewer sites of metastatic disease, and were less likely to be on opioid medications. Conclusions: In this study, we show that patients who received ADT alone as treatment for mCSPC are older, have more comorbidities, and have less extensive disease. While there has been a decline over time in the number of patients treated with ADT alone, over 50% of all patients with mCSPC continue to receive ADT alone. Further work is needed to understand barriers to treatment intensification and for knowledge translation initiatives to improve the treatment of patients with mCSPC.
format Online
Article
Text
id pubmed-10528640
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105286402023-09-28 A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS) Karim, Safiya Lowther, Jennifer Gyulay, Gabriel O’Sullivan, Dylan Wallis, Christopher J. D. Yip, Steven M. Brenner, Darren R. Boyne, Devon J. Cheung, Winson Y. Curr Oncol Article Introduction: Over the past decade, the treatment of metastatic castration-sensitive prostate cancer (mCSPC) has changed significantly. Current guidelines suggest the use of androgen deprivation therapy (ADT) plus an additional systemic therapy, regardless of disease burden and risk, based on phase 1 evidence showing improved overall survival. We sought to describe treatment patterns of patients with mCSPC in the province of Alberta. Methods: This was a retrospective, population-based, cohort study of male patients aged ≥18 with mCSPC at the time of diagnosis and who initiated ADT between 1 January 2016 and 31 December 2020. Data were obtained from the Alberta Cancer Registry. Patients were assigned to an ADT-alone cohort or a treatment intensification cohort (cohorts 2–5). The primary objectives of this study were to describe baseline characteristics and the treatment of mCSPC patients who initiated ADT with or without treatment intensification. Overall survival between cohorts was a secondary objective. Descriptive statistics were used to describe differences in baseline characteristics of each cohort. Overall survival was calculated using the Kaplan–Meier method. All statistical tests were two-sided and are used to call out likely cohort differences descriptively. Results: Between 1 January 2016 and 31 December 2020, we identified a total of 960 patients with mCSPC (median age 74 years, IQR 66–82). Most patients received ADT alone (67%), followed by ADT plus abiraterone (18%), ADT plus docetaxel (12%), and ADT plus enzalutamide or apalutamide (3%). Over the study period, we observed an increase in the utilization of treatment intensification over time, in particular, the increased use of androgen-receptor-axis-targeted (ARAT) therapies. Patients who received ADT alone were older, were more likely to have more than one comorbid condition, had fewer sites of metastatic disease, and were less likely to be on opioid medications. Conclusions: In this study, we show that patients who received ADT alone as treatment for mCSPC are older, have more comorbidities, and have less extensive disease. While there has been a decline over time in the number of patients treated with ADT alone, over 50% of all patients with mCSPC continue to receive ADT alone. Further work is needed to understand barriers to treatment intensification and for knowledge translation initiatives to improve the treatment of patients with mCSPC. MDPI 2023-09-01 /pmc/articles/PMC10528640/ /pubmed/37754506 http://dx.doi.org/10.3390/curroncol30090591 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Karim, Safiya
Lowther, Jennifer
Gyulay, Gabriel
O’Sullivan, Dylan
Wallis, Christopher J. D.
Yip, Steven M.
Brenner, Darren R.
Boyne, Devon J.
Cheung, Winson Y.
A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)
title A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)
title_full A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)
title_fullStr A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)
title_full_unstemmed A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)
title_short A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)
title_sort real-world evidence study using alberta-population-based data to describe treatment patterns for metastatic castration-sensitive prostate cancer patients (awareness)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528640/
https://www.ncbi.nlm.nih.gov/pubmed/37754506
http://dx.doi.org/10.3390/curroncol30090591
work_keys_str_mv AT karimsafiya arealworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT lowtherjennifer arealworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT gyulaygabriel arealworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT osullivandylan arealworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT wallischristopherjd arealworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT yipstevenm arealworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT brennerdarrenr arealworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT boynedevonj arealworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT cheungwinsony arealworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT karimsafiya realworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT lowtherjennifer realworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT gyulaygabriel realworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT osullivandylan realworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT wallischristopherjd realworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT yipstevenm realworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT brennerdarrenr realworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT boynedevonj realworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness
AT cheungwinsony realworldevidencestudyusingalbertapopulationbaseddatatodescribetreatmentpatternsformetastaticcastrationsensitiveprostatecancerpatientsawareness